Search

everythinglearnresearchcommunity

for

Search:↓

New cancer drugs can cause skin side effects like rashes, dry skin, hair changes, and nail problems.

Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.

Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.

The guidelines help doctors manage skin problems from certain cancer treatments to improve patients' lives.

ZD1839, a cancer drug, can cause mild skin rashes that are treatable without stopping the medication.

Gefitinib treatment led to unexpected hair growth in two lung cancer patients.

Erlotinib can cause excessive eyelash growth.

EGFR-targeting cancer drugs can cause skin rashes and other side effects.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

EGFR-TKIs can cause unexpected skin, nail, and hair issues.

Gefitinib therapy can cause unusual hair growth on the nose.

Doxycycline helps prevent skin issues from erlotinib in lung cancer patients.

Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.

Erlotinib can cause significant but temporary hair loss in lung cancer patients.

Gefitinib can cause slower, finer, brittle, and curly scalp hair.

Combining ficlatuzumab and gefitinib can cause severe scarring hair loss.

Erlotinib can cause hair loss as a side effect.

Cooling the scalp may prevent hair loss from chemotherapy, hair often grows back after treatment, and nail issues usually improve after stopping the drug.

Chemotherapy often causes skin and hair issues, but early management can help improve patient care.

EGFR inhibitors for lung cancer can cause severe skin issues.

A cancer drug called nilotinib might cause hair loss due to inflammation around hair follicles.

Drug repurposing shows promise for treating many medical conditions.

Lenvatinib and sorafenib are generally safe but need dose adjustments due to side effects.

Some leukemia treatments can cause skin reactions similar to keratosis pilaris.

Tyrosine kinases are important in skin autoimmune diseases and could be targets for new treatments.

Lung cancer biology differs between women and men, with women responding better to certain treatments.

The platform effectively grows lung cancer cell spheroids for drug testing.

Anti-acne medications may work by reducing the activity of a protein involved in acne development.

Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.

Targeted cancer therapies often cause skin reactions, so dermatologists must manage these effects.